Search clinical trials for: Sodium-Glucose Transporter 2 Inhibitors

Total 16002 results

The People's Hospital of Gaozhou

Recruiting

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

China
Instituto Nacional de Ciencias Medicas y Nutricion...
Olynka Vega Vega; Noemi del Toro Cisneros; Miguel Ángel Martínez Rojas

Recruiting

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study (DAKI-CKD)

Biomarkers | CKD | AKI - Acute Kidney Injury | Transition to CKD

Mexico
AstraZeneca

Terminated

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function. (DAPASALT)

Diabetes Mellitus, Type 2 | Kidney Function Tests

Netherlands, Sweden
AstraZeneca

Completed

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. (DAPAMAAST)

Diabetes Mellitus, Type 2 | Skeletal Muscle Insulin Sensitivity

Netherlands
AstraZeneca
Bristol-Myers Squibb

Completed

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Healthy Volunteers

Germany
Yale University
American Heart Association

Recruiting

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study (SGLT2i in CRS)

Cardiorenal Syndrome

United States
University of Campinas, Brazil

Recruiting

DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease (Dare-Esrd)

End-stage Kidney Disease

Brazil
National Institute of Allergy and Infectious Diseases...

Recruiting

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Crohn's Disease | Glycogen Metabolism | Inflammatory Bowel Disease (IBD)

United States
Sun Jia

Completed

Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.

Overweight | Carbohydrate | Sodium-glucose Transporter 2 Inhibitors

China
Fundacion para la Formacion e Investigacion Sanitarias...
Spanish Society of Cardiology

Completed

Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure . (MODA)

Heart Failure

Spain
Medical University Innsbruck
Medical University of Graz; University of Bern

Completed

Dapagliflozin in Type 1 Diabetes (DapaT1DM)

Glycemic Control | Fasting Glucose | Glucose Excursion

Austria
Boehringer Ingelheim

Completed

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus

Sweden
Huashan Hospital

Unknown

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Cardiomyopathies | Acromegaly

China
AstraZeneca
Bristol-Myers Squibb

Completed

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Renal Impairment in Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

Type2 Diabetes | High Blood Sugar

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
University of Michigan
University of Colorado, Denver; Renal Pre-Competitive Consortium (RPC3)

Recruiting

Renal Mechanism of SGLT2 Inhibition

Diabetic Kidney Disease | Type 2 Diabetes

United States
Translational Research Center for Medical Innovation...
Astellas Pharma Inc; Osaka Saiseikai Nakatsu Hospital

Completed

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes (HARUKAS)

Diabetes Mellitus, Type 2

Japan
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Heart Failure | Ventricular Dysfunction | Ventricular Remodeling

Italy
Mohamed Nabil Elkholy

Recruiting

Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

STEMI

Egypt
Chinese University of Hong Kong

Recruiting

Dapa Acute Heart Failure Study

Heart Failure

Hong Kong
China National Center for Cardiovascular Diseases

Recruiting

Dapagliflozin Therapy In Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
Children's Hospital of Fudan University

Completed

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Proteinuria

China
The University of Hong Kong

Active, not recruiting

The Effects of SGLTi on Diabetic Cardiomyopathy (SGLTi)

Type2 Diabetes | Heart Failure With Reduced Ejection Fraction

Hong Kong
University of Ioannina

Completed

Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy

Diabetes

Greece
AstraZeneca
Bristol-Myers Squibb

Completed

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Healthy

Germany
Seoul National University Hospital
AstraZeneca

Completed

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Diabetes Mellitus, Type 2

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Healthy
Unity Health Toronto
Boehringer Ingelheim; Canadian Medical and Surgical Knowledge Translation Research... and other collaborators

Completed

Empagliflozin and Cardiac Remodelling in People Without Diabetes (EMPA-HEART 2)

Cardiovascular Diseases | Left Ventricular Hypertrophy

Canada, Taiwan
RWTH Aachen University
Boehringer Ingelheim

Completed

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes (EMPA)

Diabetes Mellitus Type 2 (T2DM)

Germany
The University of The West Indies

Completed

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study. (EFFECT)

Platelet Dysfunction Due to Drugs

Trinidad and Tobago
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Netherlands, Canada
Boehringer Ingelheim

Completed

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

Empagliflozin and Sympathetic Nerve Traffic

Type 2 Diabetes Mellitus

Germany
Amir Moheet

Recruiting

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

United States
Assistance Publique Hopitaux De Marseille

Completed

Impact of Empaglifozine on Cardiac Ectopic Fat (EMPACEF)

Type 2 Diabetes

France
University of Sao Paulo

Recruiting

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Myocardial Infarction | Diabetes | Acute Coronary Syndrome | Ventricular Dysfunction

Brazil
Fayoum University
Cairo University; NewGiza University

Not yet recruiting

Prevent Diabetic Kidney Disease Among Egyptians

Diabetes Mellitus Without Complication
Colorado Prevention Center
Bayer; Saint Luke's Hospital of Kansas City

Not yet recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (CONFIRMATION)

Heart Failure
Universitas Sebelas Maret

Not yet recruiting

Dapagliflozin Effect on Rheumatic Mitral Stenosis (Dapa-Rhemis)

Heart Failure | Rheumatic Heart Disease | Mitral Stenosis

Indonesia
Minneapolis Heart Institute Foundation

Recruiting

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Heart Attack | Enlarged Heart

United States
Instituto Mexicano del Seguro Social

Recruiting

Effect of Dapagliflozin on LV Remodeling Post AMI

Myocardial Infarction

Mexico
G.Gennimatas General Hospital
2nd Department of Cardiology, "Attikon" University Hospital, National and...

Not yet recruiting

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

Catheter Ablation | Atrial Fibrillation Recurrent | Sodium-glucose Co-transporter 2 Inhibitors | Pulmonary Venous Isolation

Greece
Mayo Clinic

Completed

Dapagliflozin (DAPA) Effects in HFpEF

Heart Failure With Preserved Ejection Fraction

United States
Nanfang Hospital of Southern Medical University

Completed

Dapagliflozin Efficacy and Action in PCOS (DEAP)

Polycystic Ovary Syndrome

China
Daewoong Pharmaceutical Co. LTD.

Completed

The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. (ENHANCE-M)

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
University of Maryland, Baltimore
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Pharmacogenetics of SGLT2 Inhibitors (SGLT2iPGx)

Diabetes Mellitus | Hyperuricemia | Gout

Search clinical trials for: Sodium-Glucose Transporter 2 Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations